Prulifloxacin: A brief review of its potential in the treatment of acute exacerbation of chronic bronchitis

Francesco Blasi, Stefano Aliberti, Paolo Tarsia, PierAchille Santus, Stefano Centanni, Luigi Allegra

Research output: Contribution to journalArticlepeer-review


Exacerbations of chronic bronchitis (AECB) are a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD), and their impact on public health is increasing. The new fluoroquinolones have an excellent spectrum providing cover for the most important respiratory pathogens, including atypical and "typical" pathogens. Not surprisingly, different guidelines have inserted these agents among the drugs of choice in the empirical therapy of AECB. The pharmacokinetic and dynamic properties of the new fluoroquinolones have a significant impact on their clinical and bacteriological efficacy. They cause a concentration-dependent killing with a sustained post-antibiotic effect. This review discusses the most recent data on the new fluoroquinolone prulifloxacin and critically analyses its activity and safety in the management of AECB.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalInternational Journal of COPD
Issue number1
Publication statusPublished - 2007


  • Chronic bronchitis
  • Exacerbations
  • Prulifloxacin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Health Policy


Dive into the research topics of 'Prulifloxacin: A brief review of its potential in the treatment of acute exacerbation of chronic bronchitis'. Together they form a unique fingerprint.

Cite this